Seiji Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seiji Matsumoto has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Hirotsugu Uemura
Department of Urology, Kinki University School of Medicine, OsakaâSayama, Japan
8 shared publicationsTadashi Hanai
Urological and Urodynamics Center, Koushinkai Hospital, Sakai, Japan
8 shared publications- Hirotsugu Uemura
Department of Urology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan
5 shared publications - Nobutaka Shimizu
Pelvic Floor Center, Kochi Medical School Kochi University Nankoku Japan
3 shared publications - Koichi Sugimoto
Department of Urology, NTT West Osaka Hospital, Osaka, Japan
2 shared publications Miho Kaneko
Department of Urology, Kinki University School of Medicine
2 shared publications
Latest Publications
- 21 January 2010
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 41  (S 01) , S46-S49
Effect of Edaravone on Ischemia / Reperfusion Injury in Rat Urinary Bladder â Changes in Smooth Muscle Cell Phenotype and Contractile Function
Edaravone is a newly developed radical scavengÂing agent that has been widely used for protecÂtion against ischemia / reperfusion (I / R) injury in patients with cerebral infarction. The present study investigated the effects of edaravone on the I / R injury in rat urinary bladder. Adult male rats were divided in the four groups: groups 1â3 received 1 hour of ischemia followed by 1 hour of reperfusion with saline and with edaravone (1 and 3 mg / kg body weight), and group 4 were age-matched control rats. The in vivo ischemia was created by clamping the vesical arteries for 1 hour and reperfusion was accomplished by removing the clips and lasted for 1 hour. Edaravone or saline were administered after reperfusion for 30 min. Following reperfusion, the bladder was excised and separated. Bladder smooth muscle cell (SMC) phenotypic expression was investiÂgated in the electron microscope. The number of contractile and non-contractile bladder SMC phenoÂtype according to the morphological criteria was counted and the ratio of non-contractile to contractile phenotype was calculated. The responses to electrical field stimulation and carÂbachol were recorded. Edaravone administration resulted in the protection of the morphological changes and contractile responses to both EFS and carbachol that were affected by the agent. Our findings demonstrate that edaravone has a potentially protective effect on I / R-induced damage in the rat bladder.
- 21 January 2010
- Published by Georg Thieme Verlag KG in Aktuelle Urologie
- Vol. 41  (S 01) , S46-S49
Effect of Edaravone on Ischemia / Reperfusion Injury in Rat Urinary Bladder â Changes in Smooth Muscle Cell Phenotype and Contractile Function
Edaravone is a newly developed radical scavengÂing agent that has been widely used for protecÂtion against ischemia / reperfusion (I / R) injury in patients with cerebral infarction. The present study investigated the effects of edaravone on the I / R injury in rat urinary bladder. Adult male rats were divided in the four groups: groups 1â3 received 1 hour of ischemia followed by 1 hour of reperfusion with saline and with edaravone (1 and 3 mg / kg body weight), and group 4 were age-matched control rats. The in vivo ischemia was created by clamping the vesical arteries for 1 hour and reperfusion was accomplished by removing the clips and lasted for 1 hour. Edaravone or saline were administered after reperfusion for 30 min. Following reperfusion, the bladder was excised and separated. Bladder smooth muscle cell (SMC) phenotypic expression was investiÂgated in the electron microscope. The number of contractile and non-contractile bladder SMC phenoÂtype according to the morphological criteria was counted and the ratio of non-contractile to contractile phenotype was calculated. The responses to electrical field stimulation and carÂbachol were recorded. Edaravone administration resulted in the protection of the morphological changes and contractile responses to both EFS and carbachol that were affected by the agent. Our findings demonstrate that edaravone has a potentially protective effect on I / R-induced damage in the rat bladder.
- 7 July 2009
- Published by Wiley in Phytotherapy Research
- Vol. 24  (2) , 301-303
Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia
Eviprostat is a phytotherapeutic agent that has been used widely for more than 40 years in the treatment of benign prostatic hyperplasia (BPH) in Japan and Germany, and is known to have antioxidant activity. The present study investigated the effect of Eviprostat on the levels of the urinary oxidative stress marker 8âhydroxyâ2âČâdeoxyguanosine (8âOHdG) in a rabbit model of surgical partial bladder outlet obstruction (PBOO) and in patients with lower urinary tract symptoms (LUTS) associated with BPH. In the rabbit model, 8âOHdG levels in urine collected after 3 weeks of PBOO were 3.8âfold higher than in the urine of shamâoperated rabbits. When twiceâdaily Eviprostat was administered orally throughout the 3âweek PBOO period, the increase in urinary 8âOHdG levels was suppressed by 70%. In the clinical study, nine patients who received Eviprostat for 4 weeks showed 2.5âfold lower urinary 8âOHdG levels than before treatment. During Eviprostat treatment, the total International Prostate Symptom Score (IPSS) decreased from 16.56 ± 2.74 to 13.67 ± 2.30 and the quality of life score from 4.22 ± 0.40 to 3.22 ± 0.46. The findings provide evidence that the antioxidant activity of Eviprostat is responsible for its beneficial effects in the treatment of BPH. Copyright © 2009 John Wiley & Sons, Ltd.
- 7 July 2009
- Published by Wiley in Phytotherapy Research
- Vol. 24  (2) , 301-303
Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia
Eviprostat is a phytotherapeutic agent that has been used widely for more than 40 years in the treatment of benign prostatic hyperplasia (BPH) in Japan and Germany, and is known to have antioxidant activity. The present study investigated the effect of Eviprostat on the levels of the urinary oxidative stress marker 8âhydroxyâ2âČâdeoxyguanosine (8âOHdG) in a rabbit model of surgical partial bladder outlet obstruction (PBOO) and in patients with lower urinary tract symptoms (LUTS) associated with BPH. In the rabbit model, 8âOHdG levels in urine collected after 3 weeks of PBOO were 3.8âfold higher than in the urine of shamâoperated rabbits. When twiceâdaily Eviprostat was administered orally throughout the 3âweek PBOO period, the increase in urinary 8âOHdG levels was suppressed by 70%. In the clinical study, nine patients who received Eviprostat for 4 weeks showed 2.5âfold lower urinary 8âOHdG levels than before treatment. During Eviprostat treatment, the total International Prostate Symptom Score (IPSS) decreased from 16.56 ± 2.74 to 13.67 ± 2.30 and the quality of life score from 4.22 ± 0.40 to 3.22 ± 0.46. The findings provide evidence that the antioxidant activity of Eviprostat is responsible for its beneficial effects in the treatment of BPH. Copyright © 2009 John Wiley & Sons, Ltd.
- 1 June 2009
- Vol. 55  (6) , 311-4
[Change of lower urinary tract symptoms during pregnancy and after delivery--investigations using IPSS/QOL and Urinary Incontinence Questionnaires].
Using International Prostate Symptom Score (IPSS)/Quality of life (QOL) and Urinary Incontinence Questionnaires, we collected a total of 89 questionnaires from 48 pregnant women (average age of 31.4 +/- 3.42) and data 4 times during each pregnancy (during the 14th, 26th and 36th weeks of pregnancy) and 1 month after delivery. We examined whether there was a relationship between the number of incontinence incidences listed in the questionnaires and other parameters: the body mass index (BMI), previous deliveries, the weight of the baby delivered, the use of episiotomy, etc. The average IPSS score was 5.84 +/- 4.65, 5.33 +/- 2.73, 7.35 +/- 4.51 for the 14, 26 and 36th week, respectively and 1.82 +/- 1.76 one month after delivery. The major symptom reported was storage symptom and the scores increased as the pregnancy progressed and recovered by one month after delivery. The average score on the Urinary Incontinence Questionnaires was 3.32 +/- 2.69, 5.05 +/- 3.02, 6.15 +/- 2.89 for the 14, 26 and 36th week, respectively and 1.59 +/- 2.03 one month after delivery. The major symptom reported was stress incontinence. The scores increased significantly as the pregnancy progressed and, one month after delivery, returned to the level at the 14th week of pregnancy. We found a positive correlation between the number of incidences of incontinence at the 36th week and the subject's BMI. Among the lower urinary tract symptoms, storage symptom and stress incontinence were found in the early stage of pregnancy. Storage symptom disappeared after delivery, but stress incontinence was reduced only to the level in the early stage of pregnancy.
- 1 June 2009
- Vol. 55  (6) , 311-4
[Change of lower urinary tract symptoms during pregnancy and after delivery--investigations using IPSS/QOL and Urinary Incontinence Questionnaires].
Using International Prostate Symptom Score (IPSS)/Quality of life (QOL) and Urinary Incontinence Questionnaires, we collected a total of 89 questionnaires from 48 pregnant women (average age of 31.4 +/- 3.42) and data 4 times during each pregnancy (during the 14th, 26th and 36th weeks of pregnancy) and 1 month after delivery. We examined whether there was a relationship between the number of incontinence incidences listed in the questionnaires and other parameters: the body mass index (BMI), previous deliveries, the weight of the baby delivered, the use of episiotomy, etc. The average IPSS score was 5.84 +/- 4.65, 5.33 +/- 2.73, 7.35 +/- 4.51 for the 14, 26 and 36th week, respectively and 1.82 +/- 1.76 one month after delivery. The major symptom reported was storage symptom and the scores increased as the pregnancy progressed and recovered by one month after delivery. The average score on the Urinary Incontinence Questionnaires was 3.32 +/- 2.69, 5.05 +/- 3.02, 6.15 +/- 2.89 for the 14, 26 and 36th week, respectively and 1.59 +/- 2.03 one month after delivery. The major symptom reported was stress incontinence. The scores increased significantly as the pregnancy progressed and, one month after delivery, returned to the level at the 14th week of pregnancy. We found a positive correlation between the number of incidences of incontinence at the 36th week and the subject's BMI. Among the lower urinary tract symptoms, storage symptom and stress incontinence were found in the early stage of pregnancy. Storage symptom disappeared after delivery, but stress incontinence was reduced only to the level in the early stage of pregnancy.
- Open Access
- 27 April 2009
- Published by Wiley in BJU International
- Vol. 103  (10) , 1436-1439
Bladder outlet obstruction accelerates bladder carcinogenesis
OBJECTIVE: To examine the correlation between partial bladder outlet obstruction (PBOO) and bladder carcinogenesis. MATERIALS AND METHODS: Female Wistar rats (6 weeks old) were divided into three groups of 10 each: group 1 was exposed to nâbutylânâbutanol nitrosamine (BBN, a carcinogen) in drinking water for 8 weeks; group 2 had PBOO induced surgically after exposure to BBN for 8 weeks; group 3 had a sham operation and the rats drank normal water (control group). After 20 weeks, all of the rats were killed humanely and their bladders analysed. RESULTS: There were no significant differences in body weight among the groups. The bladder weight of group 2 was significantly greater than either group 1 or group 3. Histopathologically, bladder smooth muscle hypertrophy was the major cause of the increased bladder weight for group 2. In group 2 there were increases in bladder wall thickness and many nippleâshaped urothelial tumours. Basic fibroblast growth factor and hypoxiaâinducible factorâ1α expression were significantly greater in group 2 than in groups 1 and 3. CONCLUSIONS: Exposure of the bladder to carcinogens during bladder hyperplasia and hypertrophy induced by PBOO results in a greater incidence of superficial bladder carcinoma.
- 27 April 2009
- Published by Wiley in BJU International
- Vol. 103  (10) , 1436-1439
Open AccessBladder outlet obstruction accelerates bladder carcinogenesis
OBJECTIVE: To examine the correlation between partial bladder outlet obstruction (PBOO) and bladder carcinogenesis. MATERIALS AND METHODS: Female Wistar rats (6 weeks old) were divided into three groups of 10 each: group 1 was exposed to nâbutylânâbutanol nitrosamine (BBN, a carcinogen) in drinking water for 8 weeks; group 2 had PBOO induced surgically after exposure to BBN for 8 weeks; group 3 had a sham operation and the rats drank normal water (control group). After 20 weeks, all of the rats were killed humanely and their bladders analysed. RESULTS: There were no significant differences in body weight among the groups. The bladder weight of group 2 was significantly greater than either group 1 or group 3. Histopathologically, bladder smooth muscle hypertrophy was the major cause of the increased bladder weight for group 2. In group 2 there were increases in bladder wall thickness and many nippleâshaped urothelial tumours. Basic fibroblast growth factor and hypoxiaâinducible factorâ1α expression were significantly greater in group 2 than in groups 1 and 3. CONCLUSIONS: Exposure of the bladder to carcinogens during bladder hyperplasia and hypertrophy induced by PBOO results in a greater incidence of superficial bladder carcinoma.
- 1 April 2009
- Vol. 55  (4) , 187-91
[The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
The aims of this study were to define the relationships between prostate-specific antigen (PSA) and alpha 1-adrenergic receptor antagonist (alpha 1 blocker). A prospective clinical study of 48 male patients examined between May 2004 and December 2007 was performed. 4.0-9.9 ng/ml PSA level who had no notable clinical findings of urinary retention, urinary tract infections and prostate cancer (PC) received tamusulosin 0.2 mg once daily for 3 months, and then received prostate biopsy. We divided the patients into two groups: PC and benign prostate hyperplasia (BPH)/lower urinary tract symptom (LUTS) group. In total, the PSA level showed no significant change after treatment. In the PC group, PSA significantly increased after treatment. However, PSA decreased in the BPH/LUTS group. The alpha 1 blocker significantly improved urination status (the subjective symptoms and urodynamics parameters) in the BPH/LUTS group. In two groups, prostate volume showed no significant difference. Among those patients in the BPH/LUTS group, their urination status was significantly improved with alpha 1 blocker and their PSA level dropped slightly. On the other hand, the PSA level was significantly increased in the PC group. This study shows that by using an alpha 1 blocker, it may be possible to avoid conducting the prostate biopsy at an early stage or indeed one may not be needed at all for patients with only slight increases in PSA.
- 1 April 2009
- Vol. 55  (4) , 187-91
[The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
The aims of this study were to define the relationships between prostate-specific antigen (PSA) and alpha 1-adrenergic receptor antagonist (alpha 1 blocker). A prospective clinical study of 48 male patients examined between May 2004 and December 2007 was performed. 4.0-9.9 ng/ml PSA level who had no notable clinical findings of urinary retention, urinary tract infections and prostate cancer (PC) received tamusulosin 0.2 mg once daily for 3 months, and then received prostate biopsy. We divided the patients into two groups: PC and benign prostate hyperplasia (BPH)/lower urinary tract symptom (LUTS) group. In total, the PSA level showed no significant change after treatment. In the PC group, PSA significantly increased after treatment. However, PSA decreased in the BPH/LUTS group. The alpha 1 blocker significantly improved urination status (the subjective symptoms and urodynamics parameters) in the BPH/LUTS group. In two groups, prostate volume showed no significant difference. Among those patients in the BPH/LUTS group, their urination status was significantly improved with alpha 1 blocker and their PSA level dropped slightly. On the other hand, the PSA level was significantly increased in the PC group. This study shows that by using an alpha 1 blocker, it may be possible to avoid conducting the prostate biopsy at an early stage or indeed one may not be needed at all for patients with only slight increases in PSA.
- Open Access
- 11 March 2009
- Published by Wiley in BJU International
- Vol. 103  (7) , 987-990
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model
OBJECTIVES: To investigate whether vardenafil, a phosphodiesterase 5 (PDEâ5) inhibitor, would protect the bladder from decompensatory changes in a 4âweek rat bladder outlet obstruction (BOO) model, as evidence has been accumulating that PDEâ5 inhibitors improve lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: In all, 50 12âweekâold female SpragueâDawley rats were divided into five equal groups; group 1, sham operated vehicle control rats; group 2, BOO vehicle rats; group 3â5, BOO rats given oral vardenafil at 5, 20, 80 mg/L, respectively. Vardenafil was given in drinking water from the day of surgery. At 4âweeks after the introduction of BOO, vardenafil was washedâout by giving water for 24â48 h, and then the bladder was excised and dissected into four longitudinal strips for isometric organâbath assay. Contractile responses of bladder strips to electrical field stimulation (EFS), carbachol and KCl was determined for each group. RESULTS: BOO induced a significant increase in bladder weight in group 2 compared with group 1. Bladder weights of groups 3â5 were not significantly different from that of group 2. The contractile forces in response to EFS, carbachol and KCl in group 2 were 30.7â51.7% of those in group 1. Vardenafil treatment in groups 3â5 generally did not block the BOOâinduced reduction of contractile force in the bladder strips. However, treatment with a high dose of vardenafil resulted in a significant increase in the contractile response to carbachol (78.4% group 5 vs 51.7% group 2). CONCLUSION: Chronic treatment with a high dose of vardenafil protected the rat bladder from BOOâinduced contractile dysfunction to carbachol.
- 11 March 2009
- Published by Wiley in BJU International
- Vol. 103  (7) , 987-990
Open AccessEffects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model
OBJECTIVES: To investigate whether vardenafil, a phosphodiesterase 5 (PDEâ5) inhibitor, would protect the bladder from decompensatory changes in a 4âweek rat bladder outlet obstruction (BOO) model, as evidence has been accumulating that PDEâ5 inhibitors improve lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: In all, 50 12âweekâold female SpragueâDawley rats were divided into five equal groups; group 1, sham operated vehicle control rats; group 2, BOO vehicle rats; group 3â5, BOO rats given oral vardenafil at 5, 20, 80 mg/L, respectively. Vardenafil was given in drinking water from the day of surgery. At 4âweeks after the introduction of BOO, vardenafil was washedâout by giving water for 24â48 h, and then the bladder was excised and dissected into four longitudinal strips for isometric organâbath assay. Contractile responses of bladder strips to electrical field stimulation (EFS), carbachol and KCl was determined for each group. RESULTS: BOO induced a significant increase in bladder weight in group 2 compared with group 1. Bladder weights of groups 3â5 were not significantly different from that of group 2. The contractile forces in response to EFS, carbachol and KCl in group 2 were 30.7â51.7% of those in group 1. Vardenafil treatment in groups 3â5 generally did not block the BOOâinduced reduction of contractile force in the bladder strips. However, treatment with a high dose of vardenafil resulted in a significant increase in the contractile response to carbachol (78.4% group 5 vs 51.7% group 2). CONCLUSION: Chronic treatment with a high dose of vardenafil protected the rat bladder from BOOâinduced contractile dysfunction to carbachol.
- 1 June 2008
- Vol. 54  (6) , 453-6
[Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia].
To investigate the mechanism of the ameliorating effect of alpha1-blocker on storage symptoms associated with benign prostatic hyperplasia (BPH), we evaluated the effect of tamsulosin on the bladder blood flow in rats with bladder outlet obstruction (BOO). BOO was produced by ligature in the part around a proximal urethra and kept for 2 weeks. Tamsulosin was subcutaneously administered with an osmotic pump for 2 weeks immediately after the BOO operation. Bladder blood flow in the sham-operated rats, the control BOO rats and the tamsulosin-treated BOO rats was measured by the fluoro-microsphere method. Bladder blood flow was significantly reduced in BOO rats compared with sham-operated rats, and tamsulosin significantly increased the bladder blood flow in BOO rats. The present results suggest that the increase in bladder blood flow by tamsulosin contributes to the improvement of storage symptoms associated with BPH.
- 1 June 2008
- Vol. 54  (6) , 453-6
[Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia].
To investigate the mechanism of the ameliorating effect of alpha1-blocker on storage symptoms associated with benign prostatic hyperplasia (BPH), we evaluated the effect of tamsulosin on the bladder blood flow in rats with bladder outlet obstruction (BOO). BOO was produced by ligature in the part around a proximal urethra and kept for 2 weeks. Tamsulosin was subcutaneously administered with an osmotic pump for 2 weeks immediately after the BOO operation. Bladder blood flow in the sham-operated rats, the control BOO rats and the tamsulosin-treated BOO rats was measured by the fluoro-microsphere method. Bladder blood flow was significantly reduced in BOO rats compared with sham-operated rats, and tamsulosin significantly increased the bladder blood flow in BOO rats. The present results suggest that the increase in bladder blood flow by tamsulosin contributes to the improvement of storage symptoms associated with BPH.
- 1 May 2008
- Vol. 54  (5) , 321-4
[Distribution of elastic fiber on prostate].
We examined prostate specimens from 5 patients (median age; 71.8 years, range 57-83), with benign prostatic hyperplasia (BPH) removed during surgery, and 4 autopsied cadavers (median age at death; 68.8 years, range 46-92) who had either obstructive or neurogenic voiding dysfunction. The prostate specimens were severed anatomically into samples of the base, middle, and apex of the prostate. They served as samples for a comparative study of the distribution of elastin fibers by means of a pathology study, using the Elastica Van Gieson (EV) staining method. The number of pixels representing elastin fibers in computerized images was analyzed using Adobe Photoshop Ver. 2.0. There was a larger proportion of elastin in the area of the urethra and at the base of prostate than in the remainder of the organ. The percentage of elastin at the base of the prostate was significantly greater among BPH patients than cadavers. Thus, it was demonstrated that elastin a stromal component was increased in BPH patients.
- 1 May 2008
- Vol. 54  (5) , 321-4
[Distribution of elastic fiber on prostate].
We examined prostate specimens from 5 patients (median age; 71.8 years, range 57-83), with benign prostatic hyperplasia (BPH) removed during surgery, and 4 autopsied cadavers (median age at death; 68.8 years, range 46-92) who had either obstructive or neurogenic voiding dysfunction. The prostate specimens were severed anatomically into samples of the base, middle, and apex of the prostate. They served as samples for a comparative study of the distribution of elastin fibers by means of a pathology study, using the Elastica Van Gieson (EV) staining method. The number of pixels representing elastin fibers in computerized images was analyzed using Adobe Photoshop Ver. 2.0. There was a larger proportion of elastin in the area of the urethra and at the base of prostate than in the remainder of the organ. The percentage of elastin at the base of the prostate was significantly greater among BPH patients than cadavers. Thus, it was demonstrated that elastin a stromal component was increased in BPH patients.
- 1 March 2008
- Vol. 54  (3) , 179-84
Changes in smooth muscle cell phenotype and contractile function following ischemia-reperfusion injury in the rat urinary bladder.
Twenty-eight adult male Sprague-Dawley rats were divided into four groups: Group 1 received 1 hour (h) of bilateral ischemia alone. Groups 2 and 3 received 1 h ischemia followed by 1 and 4 h of reperfusion (I-R), respectively. Group 4 consisted of age-matched control rats. Bladder strips were studied using electrical field stimulation (EFS) and KCl stimulation. Maximal contractile responses were recorded and analyzed. Temporal patterns of changes in phenotypic (non-contractile and contractile) expression of bladder smooth muscle cells were investigated using electron microscopy. The mean ratio of non-contractile to contractile phenotype (nc/c) of smooth muscle cells (SMCs) in the control group was 0.169. In the ischemia alone group, the ratio was 0.991. In the 1 h I-R group, the ratio 0.865 whereas in 4 h I-R group the ratio 1.601. The contractile responses to EFS and KCl showed decreased responses in all groups. These results clearly demonstrated that the ratio of nc/c increased significantly in the ischemia group and further increased significantly in both I-R groups. The contractile responses decreased in all ischemic groups although the magnitude of the contractile changes did not correspond in the change of phenotype ratio.
- 1 March 2008
- Vol. 54  (3) , 179-84
Changes in smooth muscle cell phenotype and contractile function following ischemia-reperfusion injury in the rat urinary bladder.
Twenty-eight adult male Sprague-Dawley rats were divided into four groups: Group 1 received 1 hour (h) of bilateral ischemia alone. Groups 2 and 3 received 1 h ischemia followed by 1 and 4 h of reperfusion (I-R), respectively. Group 4 consisted of age-matched control rats. Bladder strips were studied using electrical field stimulation (EFS) and KCl stimulation. Maximal contractile responses were recorded and analyzed. Temporal patterns of changes in phenotypic (non-contractile and contractile) expression of bladder smooth muscle cells were investigated using electron microscopy. The mean ratio of non-contractile to contractile phenotype (nc/c) of smooth muscle cells (SMCs) in the control group was 0.169. In the ischemia alone group, the ratio was 0.991. In the 1 h I-R group, the ratio 0.865 whereas in 4 h I-R group the ratio 1.601. The contractile responses to EFS and KCl showed decreased responses in all groups. These results clearly demonstrated that the ratio of nc/c increased significantly in the ischemia group and further increased significantly in both I-R groups. The contractile responses decreased in all ischemic groups although the magnitude of the contractile changes did not correspond in the change of phenotype ratio.
- 1 September 2007
- Vol. 53  (9) , 609-12
[Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease].
Electric stimulation therapy is one of the surgical treatments for Parkinson's disease whereby a chronic stimulating electrode is placed on the subthalmic nucleus (STN). Because medical treatments centered around L-dopa have limitations in severe Parkinson's disease, electric stimulation therapy is regarded as an appropriate treatment modality. Most Parkinson's disease patients experience lower urinary tract disorders such as urgency, daytime frequency or nocturia, due to detrusor overactivity. We conducted an International Prostate Symptom Score (IPSS) analysis and a pressure flow study (PFS) on 6 patients before and after a chronic stimulating electrode was placed on the STN and evaluated how the subjective symptoms and bladder functions changed. As a result, the IPSS total value, involuntary detrusor contraction threshold volume and maximum bladder capacity were all found to significantly improve (P<0.05). The average IPSS decreased from 11.2 to 7.0. The average involuntary detrusor contraction threshold volume increased from 90.7 ml to 172.7 ml. The average maximal bladder capacity increased from 104.0 ml to 177.2 ml. These findings suggest that the STN the positively contributes to an improvement in urinary function.
- 1 September 2007
- Vol. 53  (9) , 609-12
[Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease].
Electric stimulation therapy is one of the surgical treatments for Parkinson's disease whereby a chronic stimulating electrode is placed on the subthalmic nucleus (STN). Because medical treatments centered around L-dopa have limitations in severe Parkinson's disease, electric stimulation therapy is regarded as an appropriate treatment modality. Most Parkinson's disease patients experience lower urinary tract disorders such as urgency, daytime frequency or nocturia, due to detrusor overactivity. We conducted an International Prostate Symptom Score (IPSS) analysis and a pressure flow study (PFS) on 6 patients before and after a chronic stimulating electrode was placed on the STN and evaluated how the subjective symptoms and bladder functions changed. As a result, the IPSS total value, involuntary detrusor contraction threshold volume and maximum bladder capacity were all found to significantly improve (P<0.05). The average IPSS decreased from 11.2 to 7.0. The average involuntary detrusor contraction threshold volume increased from 90.7 ml to 172.7 ml. The average maximal bladder capacity increased from 104.0 ml to 177.2 ml. These findings suggest that the STN the positively contributes to an improvement in urinary function.